Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kruppel-like factor 18 (KLF18) was described as a novel member of the KLF (Krüppel-like factor) family, which are evolutionarily conserved transcription factors with zinc finger domains involved in DNA binding and transcriptional regulation[2][3]. However, KLF18 is now considered to be a putative pseudogene arising from a localized duplication of the KLF17 gene in placental mammals[2][3]. There is currently no experimental evidence for KLF18 gene expression—no known transcript or protein product has been confirmed, and it is not considered a functional transcription factor or therapeutic target[2][3]. For these reasons, KLF18 is not recognized as an active or druggable biological target, nor does it have ascribed biological functions, disease associations, or known molecular interactions in humans[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kruppel-like factor 18 (KLF18).